Albert Bourla, AP

Covid-19 roundup: Al­bert Bourla says Pfiz­er PhI­II is at 23,000 pa­tients, sub­mis­sion com­ing end of Oc­to­ber

Months ago, pub­lic health of­fi­cials thought it could take sev­er­al months to prove a vac­cine works. Even when con­tin­u­al­ly high coro­n­avirus case counts in the US made tri­als eas­i­er to run, there was still con­cern about how quick­ly com­pa­nies would be able to en­roll vol­un­teers.

On Thurs­day, though, Pfiz­er CEO Al­bert Bourla dis­closed that, as of yes­ter­day, Pfiz­er had reached 23,000 vol­un­teers in the Phase III tri­al for their mR­NA Covid-19 vac­cine, a “sig­nif­i­cant num­ber” of whom have al­ready got­ten the sec­ond dose.  That would put Pfiz­er and their part­ner BioN­Tech just 7,000 pa­tients short of their tar­get and, Bourla said, in line to give an up­date on ef­fi­ca­cy by the end of Oc­to­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.